1. Acid-exposed and hypoxic cancer cells do not overlap but are interdependent for unsaturated fatty acid resources.
- Author
-
Głowacka K, Ibanez S, Renoult O, Vermonden P, Giolito MV, Özkan K, Degavre C, Aubert L, Guilbaud C, Laloux-Morris F, Richiardone E, Ambroise J, Bouzin C, Brusa D, Dehairs J, Swinnen J, Corbet C, Larondelle Y, and Feron O
- Subjects
- Humans, Animals, Mice, Cell Line, Tumor, Cell Hypoxia drug effects, Fatty Acids, Omega-3 metabolism, Fatty Acids, Omega-3 pharmacology, Neoplasms metabolism, Neoplasms genetics, Neoplasms drug therapy, Neoplasms pathology, Spheroids, Cellular drug effects, Spheroids, Cellular metabolism, Spheroids, Cellular pathology, Female, Organoids metabolism, Organoids drug effects, Antigens, Neoplasm, Stearoyl-CoA Desaturase metabolism, Stearoyl-CoA Desaturase genetics, Fatty Acids, Unsaturated metabolism, Fatty Acids, Unsaturated pharmacology, Ferroptosis drug effects, Carbonic Anhydrase IX metabolism, Carbonic Anhydrase IX genetics
- Abstract
Cancer cells in acidic tumor regions are aggressive and a key therapeutic target, but distinguishing between acid-exposed and hypoxic cells is challenging. Here, we use carbonic anhydrase 9 (CA9) antibodies to mark acidic areas in both hypoxic and respiring tumor areas, along with an HRE-GFP reporter for hypoxia, to isolate distinct cell populations from 3D tumor spheroids. Transcriptomic analysis of CA9-positive, hypoxia-negative cells highlights enriched fatty acid desaturase activity. Inhibiting or silencing stearoyl-CoA desaturase-1 (SCD1) induces ferroptosis in CA9-positive acidic cancer cells and delays mouse tumor growth, an effect enhanced by omega-3 fatty acid supplementation. Using acid-exposed cancer cells and patient-derived tumor organoids, we show that SCD1 inhibition increases acidic cancer cell reliance on external mono-unsaturated fatty acids, depriving hypoxic cells of essential resources. This bystander effect provides unbiased evidence for a lack of full overlap between hypoxic and acidic tumor compartments, highlighting a rationale for targeting desaturase activity in cancer., Competing Interests: Competing interests: The authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF